Keenan Fenton

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Hodgkin Lymphoma

Drug Administration

Lipopolysaccharide Induced

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Zufei Zhang, Daping Zhang, Wenchuan Guo, Keenan Fenton, Sujata Narayanan, Shweta Jain, Joy Jiang, Sharon M Castellino, Kara M Kelly, Peter D Cole, Frank G Keller, Amit Garg, Yen Lin Chia
Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-Risk Classical Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Zufei Zhang, Daping Zhang, Wenchuan Guo, Keenan Fenton, Sujata Narayanan, Shweta Jain, Joy Jiang, Sharon M Castellino, Kara M Kelly, Peter D Cole, Frank G Keller, Amit Garg, Yen Lin Chia
Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Zufei Zhang, Daping Zhang, Wenchuan Guo, Keenan Fenton, Sujata Narayanan, Shweta Jain, Joy Jiang, Sharon M Castellino, Kara M Kelly, Peter D Cole, Frank G Keller, Amit Garg, Yen Lin Chia
Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Zufei Zhang, Daping Zhang, Wenchuan Guo, Keenan Fenton, Sujata Narayanan, Shweta Jain, Joy Jiang, Sharon M Castellino, Kara M Kelly, Peter D Cole, Frank G Keller, Amit Garg, Yen Lin Chia
Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)